
Diego Díaz García/X
May 14, 2025, 09:05
Diego A. Díaz García: Perioperative therapy is reshaping early-stage oncogene-driven NSCLC
Diego A. Díaz García, Medical Oncologist, CEO and Founder at CánCare, shared a post on X about recent paper Teja Voruganti and colleagues authored:
“Perioperative therapy is reshaping early-stage oncogene-driven NSCLC.
EGFR+ disease has adjuvant osimertinib – but what about ALK, BRAF, KRAS?
Should TKIs replace or complement chemo-IO?
Molecular testing, MRD, and smarter sequencing are key. More answers coming soon.”
Title: Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions
Journal: American Society of Clinical Oncology Educational Book
Authors: Teja Voruganti, Rosalyn Marar, Benjamin Bleiberg, Edoardo Garbo, Biagio Ricciuti, Kaushal Parikh, and Charu Aggarwal
More posts featuring NSCLC on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 14, 2025, 08:56
May 14, 2025, 08:22